Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2011

View Archived Issues

Novel phosphodiesterase 10A inhibitors synthesized

Lotus Tissue Repair raises funds to advance treatment for dystrophic epidermolysis bullosa

Johns Hopkins University and Innogene Kalbiotech begin trial for lung cancer vaccine

ISC-4 exhibits safety and antitumor activity in murine model of human colon cancer

Preclinical study supports further evaluation of dovitinib in Waldenstrom's macroglobulinemia

Leukothera shows synergistic activity with chemotherapeutic agents in leukemia cell lines

New lysophospholipid S1P1 receptor agonists presented by Almirall

Roche discloses new glycogen synthase activators

Bristol-Myers Squibb and Innate Pharma enter global agreement for IPH-2102

INV-144 enters phase IIa trial to slow kidney disease in patients with hypertension and diabetes

Novel nuclear receptor related 1 receptor ligands patented by Sanofi

Novel PI3K inhibitors prepared

Dainippon Sumitomo and AstraZeneca claim new Toll-like receptor modulators

Vantia Therapeutics raises funds to develop VA-106483 and VA-111913

Roche discloses novel series of monoamine reuptake inhibitors

Dual mTORC1/mTORC2 inhibition may enhance treatment of acute myeloid leukemia

Metabolic Solutions receives funds from the Alzheimer's Drug Discovery Foundation

Zafgen secures financing for phase II trial in obesity

INNO-206 shows safety in ongoing phase Ib trial in soft tissue sarcoma

IDMC recommmends continuation of phase III VENICE trial of Zaltrap in advanced prostate cancer

Merck KGaA to discontinue development of Toll-like receptor 9 agonist IMO-2055

Amylin Pharmaceuticals, Lilly and Alkermes report on tQT study of Bydureon

Phase III EXIST-1 trial of Afinitor in tuberous sclerosis meets primary endpoint

TMC-435 receives FDA fast track status in chronic hepatitis C genotype 1

Amsterdam Molecular Therapeutics requests reexamination of MAA for gene therapy Glybera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026